Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)

BACKGROUND: We conducted a phase II trial to evaluate the efficacy of dasatinib, a multitargeted tyrosine kinase inhibitor, for adults with recurrent glioblastoma (GBM). METHODS: Eligibility requirements were Karnofsky performance status ≥60%; no concurrent hepatic enzyme-inducing anticonvulsants; p...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Lassman, Andrew B., Pugh, Stephanie L., Gilbert, Mark R., Aldape, Kenneth D., Geinoz, Sandrine, Beumer, Jan H., Christner, Susan M., Komaki, Ritsuko, DeAngelis, Lisa M., Gaur, Rakesh, Youssef, Emad, Wagner, Henry, Won, Minhee, Mehta, Minesh P.
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2015
主題:
Clinical Investigations
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762006/
https://ncbi.nlm.nih.gov/pubmed/25758746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nov011
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料